Glimepiride 1.00 mg + Voglibose 0.20 mg + Metformin 500.00 mg

GLIMDA MV 1 is a fixed dose combination medication that combines Voglibose, Metformin, and Glimepiride. Voglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by delaying the absorption of carbohydrates in the intestine. Metformin is a biguanide that helps improve insulin sensitivity and reduce glucose production in the liver. Glimepiride is a sulfonylurea that stimulates insulin release from the pancreas. Together, these medications work synergistically to manage type 2 diabetes mellitus by controlling blood sugar levels. GLIMDA MV 1 is prescribed to improve glycemic control and reduce the risk of complications associated with diabetes.

Take GLIMDA MV 1 orally with meals, as directed by your doctor. The dosage is based on your medical condition and response to treatment. It is important to follow a balanced diet and exercise regularly while taking this medication.

Allopathic

The contents and information provided here are solely intended to provide a general overview of the products and medicines and must be used for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. The information contained herein should not be used as a substitute for the advice of a qualified physician. For all queries or doubts related to your medical condition, we highly recommend that you consult your registered medical practitioner.